Sign In
Last checked at 
6 Mar 2025 07:00
This announcement contains inside informationfor the purposes of UK Market Abuse Regulation.
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Notice of Results & Investor Presentations
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, will announce its full year results for the year ended 31 December 2024, on Tuesday 25 March 2025.
Investor presentation
Julian Baines, Executive Chair, and Stephen Young, CFO, will present the Company's results in two separate events open to all investors. The same presentation will be given at both events, which are being held at different times to offer convenient options for those wishing to attend.
Two presentations will take place on Tuesday 25 March 2025 at the following times, the first will be held online via the Investor Meet Company platform and the second will be held in-person in the City of London, full details below:
1. Investor Meet Company online presentation
EKF management will provide a live online presentation relating to the final results via Investor Meet Company at 4.15pm on Tuesday 25 March 2025. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet EKF via:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.
2. In-person investor presentation
EKF management will provide an in-person presentation relating to the Company's final results at 5.30pm on Tuesday 25 March 2025, which is open to all existing and potential shareholders. The Company welcomes investors to 75 King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm start and will be followed by refreshments.
If you would like to attend, please contact Walbrook PR on 020 7933 8780 or email EKF@walbrookpr.com.
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | ||
Julian Baines, Executive Chair / Stephen Young, CFO | via Walbrook PR | ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | ||
Phil Davies / Oliver Platts | |||
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | ||
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
● | Point-of-Care analysers in the key areas of Hematology and Diabetes |
● | Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Follow the stocks
